MISSIONPHARMA A/S: Financial statements 2014
CVR: 26902398
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
MISSIONPHARMA A/S (CVR 26902398) has filed annual accounts for 2014. In 2014, the company reported revenue of DKK 703,768,000 and a net result of DKK 69,003,000 compared with DKK 44,083,000 the year before. That is an increase of 30.8% compared with the year before. The profit margin was 9.8%. Equity in the 2014 report amounted to DKK 162,346,000. The solvency ratio was 51.1%. The company had 42 employees in the financial year.
- Revenue
- DKK 703,768,000
- Gross Profit
- DKK 129,537,000
- Profit/Loss
- DKK 69,003,000
- Equity
- DKK 162,346,000
- Total Assets
- DKK 317,641,000
- Employees
- 42
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | 703.8 mio. | 129.5 mio. | 69 mio. | 162.3 mio. | 42 |
| 2013 | 537.9 mio. | 106.1 mio. | 44.1 mio. | 124.4 mio. | 45 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
MISSIONPHARMA A/S has published its annual report for 2013. Revenue came to DKK 537,927,000, and the net result was DKK 44,083,000.
As of May 27, 2014, KPMG P/S has been appointed auditor of MISSIONPHARMA A/S.
As of May 27, 2014, EY Godkendt Revisionspartnerselskab has stepped down as auditor of MISSIONPHARMA A/S.
About MISSIONPHARMA A/S
MISSIONPHARMA A/S is a Danish company of the type Aktieselskab based in Lynge, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jean-Marc Pierre René Leccia and Edouard Marc Marie Favreau. The board consists of Eric Pierre Jean Muris (chair), Kim Erik Ginnerup, Ilona Maureen Fischer and Jean-Marc Pierre René Leccia. The company is owned by CFAO HEALTHCARE SA. The company has 67 employees (2026). In 2026, the company reported revenue of DKK 934,465,000 and a net result of DKK 120,205,000 compared with DKK 73,402,000 the year before. Equity in the 2026 report amounted to DKK 317,751,000.